Patents Assigned to Sugen, Inc.
  • Azaindole tyrosine kinase inhibitors
    Patent number: 6849641
    Abstract: The present invention relates to novel 3-hetero-arylideneazaindolin-2-one compounds and physiologically acceptable salts and prodrugs thereof which are expected to modulate the activity of protein tyrosine kinases and therefore to be useful in the prevention and treatment of protein tyrosine kinase related cellular disorders such as cancer.
    Type: Grant
    Filed: November 12, 1998
    Date of Patent: February 1, 2005
    Assignee: Sugen, Inc.
    Inventors: Peng Cho Tang, Li Sun, Gerald McMahon
  • Methods for treating diseases and disorders related to unregulated angiogenesis and/or vasculogenesis
    Patent number: 6846839
    Abstract: The present invention relates to methods for treating diseases and disorders related to unregulated angiogenesis and/or vasculogenesis. More specifically, this invention relates to methods for treating diseases and disorders, such as rheumatoid arthritis, endometriosis, ocular neovascularization, solid tumor growth and metastases, and excessive scarring during wound healing, with indolinone compounds.
    Type: Grant
    Filed: June 16, 1999
    Date of Patent: January 25, 2005
    Assignee: Sugen, Inc.
    Inventors: Peng Cho Tang, Li Sun, Laura Kay Shawver, Klaus Peter Hirth, Annie Fong
  • Diagnosis and treatment of PTP04 related disorders
    Patent number: 6844177
    Abstract: The present invention relates to PTP04 polypeptides, nucleic acids encoding such polypeptides, cells, tissues and animal containing such nucleic acids, antibodies to such polypeptides, assays utilizing such polypeptides, and methods relating to all of the foregoing. Methods for treatment, diagnosis, and screening are provided for PTP04 related diseases or conditions characterized by an abnormal interaction between a PTP04 binding partner.
    Type: Grant
    Filed: April 2, 2001
    Date of Patent: January 18, 2005
    Assignee: Sugen, Inc.
    Inventors: Bahija Jallal, Gregory D. Plowman
  • Diagnosis and treatment of AUR1 and/or AUR2 related disorders
    Patent number: 6841579
    Abstract: The present invention relates to AUR1 and/or AUR2 polypeptides, nucleic acids encoding such polypeptides, cells, tissues and animals containing such nucleic acids, antibodies to such polypeptides, assays utilizing such polypeptides, and methods relating to all of the foregoing. Methods for treatment, diagnosis, and screening are provided for AUR1 and/or AUR2 related diseases or conditions characterized by an abnormal interaction between a AUR1 and/or AUR2 polypeptide and a AUR1 and/or AUR2 binding partner.
    Type: Grant
    Filed: February 16, 2001
    Date of Patent: January 11, 2005
    Assignee: Sugen, Inc.
    Inventors: Gregory Plowman, James Bischof
  • Diangnosis and treatment of AUR1 and/or AUR2 related disorders
    Publication number: 20040265852
    Abstract: The present invention relates to AUR1 and/or AUR2 polypeptides, nucleic acids encoding such polypeptides, cells, tissues and animals containing such nucleic acids, antibodies to such polypeptides, assays utilizing such polypeptides, and methods relating to all of the foregoing. Methods for treatment, diagnosis, and screening are provided for AUR1 and/or AUR2 related diseases or conditions characterized by an abnormal interaction between a AUR1 and/or AUR2 polypeptide and a AUR1 and/or AUR2 binding partner.
    Type: Application
    Filed: December 15, 2003
    Publication date: December 30, 2004
    Applicant: SUGEN, INC.
    Inventors: Gregory Plowman, James Bischof
  • 3-(4,5,6,7-tetrahydroindol-2-ylmethylidiene)-2-indolinone derivatives as kinase inhibitors
    Publication number: 20040266855
    Abstract: The present invention relates to certain 3-(4,5,6,7-tetrahydroindol-2-yl-methylidene)-2-indolinone derivatives that inhibit kinases, in particular Src kinase. Pharmaceutical compositions comprising these compounds, methods of treating diseases mediated by kinases utilizing pharmaceutical compositions comprising these compounds, and methods of preparing them are also disclosed.
    Type: Application
    Filed: July 13, 2004
    Publication date: December 30, 2004
    Applicant: SUGEN, INC.
    Inventors: Congxin Liang, Huiping Guan, Peng Cho Tang, Robert A. Blake
  • Sulfonamide substituted indolinones as inhibitors of DNA dependent protein kinase (DNA-PK)
    Publication number: 20040266843
    Abstract: The present invention relates generally to the field of radiosensitizing agents which are capable of enhancing radiotherapy by inhibiting DNA-PK (DNA-protein kinase). In particular, it relates to sulfonamide substituted indolinones which inhibit DNA-PK.
    Type: Application
    Filed: March 8, 2004
    Publication date: December 30, 2004
    Applicant: Sugen, Inc.
    Inventors: Anthony R. Howlett, Audie Rice, Deborah Moshinsky, Ola Hammarsten
  • PYK2 and inflammation
    Publication number: 20040259158
    Abstract: The present invention relates generally to the fields of immunology and medicine, and more specifically to the field of cellular signal transduction. The present invention relates, inter alia, to methods for diagnosis, treatment, and identification of therapeutics for particular inflammation-related diseases or disorders characterized by an interaction between a PYK2 polypeptide and a natural binding partner.
    Type: Application
    Filed: February 27, 2004
    Publication date: December 23, 2004
    Applicants: Sugen, Inc., New York University
    Inventors: Joseph Schlessinger, Mitsuhiko Okigaki, Mikhail Gishizky
  • Method and compositions for inhibiting cell proliferative disorders
    Publication number: 20040242684
    Abstract: The present invention concerns compounds and their use to inhibit the activity of a receptor tyrosine kinase. The invention is preferably used to treat cell proliferative disorders such as cancers charcterized by over-activity or inappropriate activity HER2 or EGFR.
    Type: Application
    Filed: June 25, 2003
    Publication date: December 2, 2004
    Applicants: Yissum Research Development Company of the Hebrew University of Jerusalem, SUGEN, Inc.
    Inventors: Hui Chen, Aviv Gazit, Alexander Levitzki, Klaus Peter Hirth, Elaina Mann, Laura K. Shawver, Jianming Tsai, Peng Cho Tang
  • Diagnosis and treatment of ALK-7 related disorders
    Publication number: 20040234540
    Abstract: The present invention relates to ALK-7 polypeptides, nucleic acids encoding such polypeptides, cells, tissues and animals containing such nucleic acids, antibodies to such polypeptides, assays utilizing such polypeptides, and methods relating to all of the foregoing. Methods for treatment, diagnosis, and screening are provided for ALK-7 related diseases or conditions characterized by an abnormal interaction between an ALK-7 polypeptide and an ALK-7 binding partner.
    Type: Application
    Filed: May 20, 2004
    Publication date: November 25, 2004
    Applicant: SUGEN, INC.
    Inventors: Gregory D. Plowman, Douglas Clary
  • Diagnosis and treatment of alk-7 related disorders
    Patent number: 6818440
    Abstract: The present invention relates to ALK-7 polypeptides, nucleic acids encoding such polypeptides, cells, tissues and animals containing such nucleic acids, antibodies to such polypeptides, assays utilizing such polypeptides, and methods relating to all of the foregoing. Methods for treatment, diagnosis, and screening are provided for ALK-7 related diseases or conditions characterized by an abnormal interaction between an ALK-7 polypeptide and an ALK-7 binding partner.
    Type: Grant
    Filed: April 27, 1998
    Date of Patent: November 16, 2004
    Assignee: Sugen, Inc.
    Inventors: Gregory D. Plowman, Douglas Clary
  • PAK5 screening methods
    Publication number: 20040224323
    Abstract: The present invention relates to the nucleic acid molecules encoding an STE20-related family of novel protein kinases, ZC1, ZC2, ZC3, ZC4, STLK2, STLK3, STLK4, STLK5, STLK6, STLK7, KHS2, SULU1, SULU3, GEK2, PAK4 and PAK5, segments and domains thereof, as well as various methods useful for the diagnosis and treatment of various kinase-related diseases and conditions. Mammalian nucleic acid molecules encoding these kinases are particularly disclosed, and more specifically human sources of these nucleic acids are disclosed.
    Type: Application
    Filed: December 2, 2003
    Publication date: November 11, 2004
    Applicant: SUGEN, Inc.
    Inventors: Gregory Plowman, Ricardo Martinez, David Whyte
  • Diagnosis and treatment of ALK-7 related disorders
    Publication number: 20040219139
    Abstract: The present invention relates to ALK-7 polypeptides, nucleic acids encoding such polypeptides, cells, tissues and animals containing such nucleic acids, antibodies to such polypeptides, assays utilizing such polypeptides, and methods relating to all of the foregoing. Methods for treatment, diagnosis, and screening are provided for ALK-7 related diseases or conditions characterized by an abnormal interaction between an ALK-7 polypeptide and an ALK-7 binding partner.
    Type: Application
    Filed: May 20, 2004
    Publication date: November 4, 2004
    Applicant: SUGEN, INC.
    Inventors: Gregory D. Plowman, Douglas Clary
  • Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhbitors
    Publication number: 20040220189
    Abstract: The present invention relates to 8-amino-aryl-substituted imidazopyrazines which modulate the activity of protein kinases (“PKs”). The compounds of this invention are therefore useful in treating disorders related to abnormal PK activity. Pharmaceutical compositions comprising these compounds, methods of treating diseases utilizing pharmaceutical compositions comprising these compounds and methods of preparing them are also disclosed.
    Type: Application
    Filed: February 20, 2004
    Publication date: November 4, 2004
    Applicant: Sugen, Inc.
    Inventors: Connie Li Sun, Congxin Liang, Ping Huang, G. Davis Harris, Huiping Guan
  • Treatment of excessive osteolysis with indolinone compounds
    Publication number: 20040209937
    Abstract: Compounds of Formula I and Formula II, as described herein, are useful for treating excessive osteolysis, by inhibiting M-CSF mediated osteoclast development. The compounds also are useful for inhibiting phosphorylation of CSF1R, and for treating cancers that express CSF1R.
    Type: Application
    Filed: February 19, 2004
    Publication date: October 21, 2004
    Applicant: SUGEN, INC.
    Inventors: Lesley Murray, Anne-Marie O'Farrell, Tinya Abrams
  • 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors
    Publication number: 20040204407
    Abstract: The present invention relates to 5-sulfonamido substituted indolinones that modulate the activity of protein kinases (“PKs”). The compounds of this invention are therefore useful in treating disorders related to abnormal PK activity. Pharmaceutical compositions comprising these compounds, methods of treating diseases utilizing pharmaceutical compositions comprising these compounds and methods of preparing them are also disclosed.
    Type: Application
    Filed: March 8, 2004
    Publication date: October 14, 2004
    Applicant: SUGEN Inc.
    Inventors: Peng Cho Tang, Congxin Liang, Todd Miller, Kenneth E. Lipson
  • Novel Kinases
    Publication number: 20040197792
    Abstract: The present invention relates to kinase polypeptides, nucleotide sequences encoding the kinase polypeptides, as well as various products and methods useful for the diagnosis and treatment of various kinase-related diseases and conditions. Through the use of a bioinformatics strategy, mammalian members of the of PTK's and STK's have been identified and their protein structure predicted.
    Type: Application
    Filed: July 15, 2003
    Publication date: October 7, 2004
    Applicant: SUGEN, INC.
    Inventors: David Whyte, Gerard Manning, Sean Caenepeel
  • Prodrugs of a 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
    Patent number: 6797725
    Abstract: The present invention relates to pyrrole substituted 2-indolinone compounds and their pharmaceutically acceptable salts which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.
    Type: Grant
    Filed: April 9, 2002
    Date of Patent: September 28, 2004
    Assignee: Sugen, Inc.
    Inventors: Connie Li Sun, Chung Chen Wei, Peng Cho Tang, Marcel Koenig, Yong Zhou, Tomas Vojkovsky, Asaad S. Nematalla
  • Crystals of the tyrosine kinase domain of non-insulin receptor tyrosine kinases
    Publication number: 20040185547
    Abstract: Crystals of the tyrosine kinase domain of cytoplasmic tyrosine kinases and receptor tyrosine kinases that undergo ligand-mediated receptor dimerization are provided. In particular, crystals of a mutant of the tyrosine kinase domain of fibroblast growth factor receptor 1 (FLGK), alone and in complex with a non-hydrolyzable adenosine triphosphate analogue, are provided. Also provided are the high resolution three dimensional structures of crystalline FLGK, both alone and in co-complex with the adenosine triphosphate analogue, as determined by X-ray diffraction.
    Type: Application
    Filed: January 26, 2004
    Publication date: September 23, 2004
    Applicants: SUGEN, INC., NEW YORK UNIVERSITY
    Inventors: Moosa Mohammadi, Joseph Schlessinger, Stevan R. Hubbard
  • Hexahydro-cyclohepta-pyrrole oxindole as potent kinase inhibitors
    Publication number: 20040186160
    Abstract: The present invention is directed to a class indolinone compounds, hexahydro-cyclohepta-pyrrole oxindoles, which are useful as protein kinase inhibitors.
    Type: Application
    Filed: December 12, 2003
    Publication date: September 23, 2004
    Applicant: SUGEN, Inc.
    Inventors: Peng Cho Tang, Yi Xia, Rachael Hawtin